D. J. Drucker

Endocrinology, Diabetes and Metabolism · 2000–2019

A researcher in the Science corpus: 19 papers; trusts 5 researchers and is trusted by 23 researchers here, as inferred from the citation graph.

Subfields

• Endocrinology, Diabetes and Metabolism — 114 citations into it; #27 of 623 by trust here, #74 by citations
• Molecular Biology — 68 citations into it; #3,829 of 17,773 by trust here, #6,685 by citations
• Surgery — 61 citations into it; #38 of 1,106 by trust here, #108 by citations
• Cardiology and Cardiovascular Medicine — 33 citations into it
• Endocrine and Autonomic Systems — 25 citations into it
• Cellular and Molecular Neuroscience — 16 citations into it; #2,717 of 2,998 by trust here, #1,899 by citations
• Oncology — 9 citations into it; #385 of 1,698 by trust here, #902 by citations

Whom D. J. Drucker trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. Jonathan E. Campbell
2. John B. Buse
3. Jens J. Holst
4. Ralph DeFronzo
5. M. Nauck
6. R. Ratner
7. M. During

Who trusts D. J. Drucker overall

1. M. Nauck
2. Ralph DeFronzo
3. J. Lovshin
4. Jens J. Holst
5. Wook Kim
6. J. Meier
7. S. Kahn
8. Jonathan E. Campbell
9. S. Swallow
10. Nur Samsu

Papers from D. J. Drucker's perspective

Ordered by how strongly the researchers D. J. Drucker trusts endorse each paper. Same corpus, a different order for every researcher.

1. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection (Nature Medicine)
2. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. (Endocrinology)
3. Inhibition of gastric inhibitory polypeptide signaling prevents obesity (Nature Medicine)
4. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes (Nature Genetics)
5. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells (Nature Medicine)
6. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. (New England Journal of Medicine)
7. The physiology of glucagon-like peptide 1. (Physiological Reviews)
8. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. (Current Medical Research and Opinion)
9. The Molecular Biology of Memory Storage: A Dialogue Between Genes and Synapses (Science)
10. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. (Diabetes)

Their papers

• The biology of incretin hormones. (2006) — 2,242 citations
• Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. (2010) — 641 citations
• Pharmacology, physiology, and mechanisms of incretin hormone action. (2013) — 1,381 citations
• Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans (2013) — 636 citations
• Incretin-based therapies for type 2 diabetes mellitus (2009) — 725 citations
• Glucagon-like peptide 1 (GLP-1) (2019) — 1,265 citations
• Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. (2018) — 1,744 citations
• FTO Obesity Variant Circuitry and Adipocyte Browning in Humans (2015) — 1,268 citations
• Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells (2011) — 882 citations
• Normalization of Obesity-Associated Insulin Resistance through Immunotherapy: CD4+ T Cells Control Glucose Homeostasis (2009) — 788 citations
• A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. (2009) — 604 citations
• Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. (2008) — 1,079 citations
• Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways (2008) — 1,050 citations
• The role of gut hormones in glucose homeostasis. (2007) — 664 citations
• Biology of incretins: GLP-1 and GIP. (2007) — 3,607 citations
• The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. (2006) — 3,807 citations
• Glucagon-like peptide-1 receptor is involved in learning and neuroprotection (2003) — 849 citations
• Enhancing incretin action for the treatment of type 2 diabetes. (2003) — 620 citations
• Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. (2000) — 607 citations